LifeMD (NASDAQ:LFMD) Given New $9.00 Price Target at HC Wainwright

LifeMD (NASDAQ:LFMD) had its target price lowered by analysts at HC Wainwright from $13.00 to $9.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 126.87% from the stock’s previous close.

Several other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LifeMD in a research report on Wednesday, October 8th. Lake Street Capital lowered their price objective on shares of LifeMD from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday. KeyCorp cut their target price on shares of LifeMD from $12.00 to $8.00 and set an “overweight” rating for the company in a research note on Wednesday. B. Riley reduced their price target on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday. Finally, BTIG Research dropped their price objective on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.43.

LifeMD Stock Performance

LifeMD stock traded down $0.12 on Wednesday, reaching $3.97. 609,431 shares of the stock were exchanged, compared to its average volume of 1,534,144. The company has a current ratio of 0.77, a quick ratio of 0.72 and a debt-to-equity ratio of 9.21. LifeMD has a twelve month low of $3.43 and a twelve month high of $15.84. The firm has a fifty day moving average price of $6.01 and a two-hundred day moving average price of $8.68. The stock has a market cap of $188.10 million, a PE ratio of -23.31 and a beta of 1.57.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Monday, November 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $60.17 million during the quarter, compared to the consensus estimate of $62.07 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that LifeMD will post -0.56 EPS for the current year.

Insiders Place Their Bets

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total value of $444,000.00. Following the sale, the insider owned 605,000 shares of the company’s stock, valued at $3,581,600. The trade was a 11.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 18.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LifeMD

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC boosted its position in shares of LifeMD by 17.5% during the 1st quarter. CWM LLC now owns 9,050 shares of the company’s stock valued at $49,000 after acquiring an additional 1,351 shares in the last quarter. Nisa Investment Advisors LLC raised its position in LifeMD by 148.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock worth $50,000 after purchasing an additional 2,185 shares in the last quarter. Quarry LP bought a new position in LifeMD during the third quarter worth about $52,000. Tower Research Capital LLC TRC boosted its holdings in LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares in the last quarter. Finally, King Wealth Management Group acquired a new stake in LifeMD during the third quarter valued at approximately $68,000. 35.52% of the stock is owned by institutional investors.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.